Continue

Ω Gynecologic oncology † Medical oncology § Radiotherapy/Radiation oncology ≠ Pathology * Writing committee member
Version 2.2015, 09/18/14 © National Comprehensive Cancer Network, Inc. 2014, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
NCCN Guidelines Version 2.2015 Table of Contents Cervical Cancer
NCCN Cervical Cancer Panel Members Summary of the Guidelines Updates Clinical Stage (CERV-1) Stage IA1 (no LVSI), Stage IA1 (with LVSI) and Stage IA2, Stage IB1 (Fertility Sparing) (CERV-2) Stage IA1 (no LVSI), Stage IA1 (with LVSI) and Stage IA2 (Non-Fertility Sparing) (CERV-3) Stage IB1 and Stage IIA1 (Non-Fertility Sparing) (CERV-4) Stage IB2 and Stage IIA2 (Non-Fertility Sparing) (CERV-4) Stage IB2, Stage IIA2, and Stages IIB, IIIA, IIIB, IVA (CERV-6) Incidental Finding of Invasive Cancer After Simple Hysterectomy (CERV-9) Surveillance (CERV-10) Local/Regional Recurrence (CERV-11) Distant Metastases (CERV-12) Principles of Evaluation and Surgical Staging (CERV-A) Principles of Radiation Therapy for Cervical Cancer (CERV-B) Sedlis Criteria: Eligibility For Considering External Pelvic Radiation After Radical Hysterectomy In Node Negative, Margin Negative, Parametria Negative Cases (CERV-C) Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-D)
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Cervical Cancer
Version 2.2015
Continue
Version 2.2015, 09/18/14 © National Comprehensive Cancer Network, Inc. 2014, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
Printed by Peng Gao on 9/28/2014 10:01:33 AM. For personal use only. Not approved for distribution. Copyright © 2014 National Comprehensive Cancer Network, Inc., All Rights Reserved.
NCCN Guidelines Version 2.2015 Panel Members Cervical Cancer
* Wui-Jin Koh, MD/Co-Chair § Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance * Benjamin E. Greer, MD/Co-Chair Ω Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance Nadeem R. Abu-Rustum, MD Ω Memorial Sloan Kettering Cancer Center Sachin M. Apte, MD, MS Ω Moffitt Cancer Center Susana M. Campos, MD, MPH, MS † Dana-Farber/Brigham and Women’s Cancer Center Kathleen R. Cho, MD ≠ University of Michigan Comprehensive Cancer Center Christina Chu, MD Ω Fox Chase Cancer Center David Cohn, MD Ω The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Marta Ann Crispens, MD Ω Vanderbilt-Ingram Cancer Center NCCN Lauren Gallagher, RPh, PhD Jillian Scavone, PhD Nicole McMillian, MS NCCN Guidelines Panel Disclosures Oliver Dorigo, MD, PhD Ω Stanford Cancer Institute Patricia J. Eifel, MD § The University of Texas MD Anderson Cancer Center Christine M. Fisher, MD, MPH § University of Colorado Cancer Center Peter Frederick, MD Ω Roswell Park Cancer Institute David K. Gaffney, MD, PhD § Huntsman Cancer Institute at the University of Utah Ernest Han, MD, PhD Ω City of Hope Comprehensive Cancer Center Warner K. Huh, MD Ω University of Alabama at Birmingham Comprehensive Cancer Center John R. Lurain, III, MD Ω Robert H. Lurie Comprehensive Cancer Center of Northwestern University David Mutch, MD Ω Siteman Cancer Center at BarnesJewish Hospital and Washington University School of Medicine
NCCN Guidelines Index Cervical Cancer TOC Discussion
Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. To find clinical trials online at NCCN Member Institutions, click here: /clinical_trials/physician.html. NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified. See NCCN Categories of Evidence and Consensus.
Printed by Peng Gao on 9/28/2014 10:01:33 AM. For personal use only. Not approved for distribution. Copyright © 2014 National Comprehensive Cancer Network, Inc., All Rights Reserved.
Staging (ST-1)
The NCCN Guidelines for Cervical Cancer include the management of squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix.
The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2014.